Swiss National Bank Decreases Stake in ADMA Biologics Inc $ADMA

Swiss National Bank decreased its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 1.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 454,000 shares of the biotechnology company’s stock after selling 4,400 shares during the period. Swiss National Bank owned approximately 0.19% of ADMA Biologics worth $8,267,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the company. SVB Wealth LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter worth about $35,000. Cullen Frost Bankers Inc. lifted its holdings in shares of ADMA Biologics by 112.5% in the second quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,081 shares in the last quarter. Toth Financial Advisory Corp grew its position in shares of ADMA Biologics by 1,081.6% in the second quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 2,293 shares during the last quarter. Ameritas Advisory Services LLC acquired a new stake in shares of ADMA Biologics in the second quarter valued at approximately $46,000. Finally, Smartleaf Asset Management LLC increased its stake in shares of ADMA Biologics by 161.4% during the 1st quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,493 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings cut ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $28.50.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $19.12 on Friday. The stock has a fifty day moving average price of $15.56 and a 200 day moving average price of $17.28. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67. The firm has a market capitalization of $4.55 billion, a P/E ratio of 22.23 and a beta of 0.40.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. The company had revenue of $134.22 million during the quarter, compared to analysts’ expectations of $131.20 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm’s revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.15 EPS. ADMA Biologics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.